Skip to search formSkip to main contentSkip to account menu

GR-20263

Known as: GR 20263, GR20263 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ceftazidime

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
In vitro activity of ceftazidime (GR 20263) and other β-lactam antibiotics against Haemophilus influenzae
SummaryMinimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) were determined for ceftazidime (GR… 
1982
1982
In vitro comparative activity of moxalactam, GR 20263, and N-formimidoyl thienamycin to other beta-lactam antibiotics and tobramycin against enterobacteriaceae and staphylococci.
The in vitro activities of moxalactam, GR 20263, and N-formimidoyl thienamycin were compared to those of cephalothin, cefazolin… 
1981
1981
Activity of ceftazidime (GR 20263) against nosocomially important pathogens
Ceftazidime was considerably more active than cefuroxime against 180 strains of resistant species of nosocomial gram-negative… 
1981
1981
Antibacterial activity of ceftazidime (GR 20263) against routine hospital isolates and highly resistant strains of enterobacteriaceae and Pseudomonas aeruginosa.
Ceftazidime was found to be highly active against routine hospital isolates of strains of Enterobacteriaceae such as Escherichia… 
1981
1981
Clinical and bacteriological evaluation of ceftazidime (GR 20263) as an antipseudomonal drug.
Ceftazidime was evaluated as an antipseudomonal drug, in a non-comparative study including 10 men and 4 women, at a daily dose of… 
1981
1981
Ceftazidime (GR 20263), a new cephalosporin derivative with excellent activity against Pseudomonas and Enterobacteriaceae.
Highly Cited
1980
Highly Cited
1980
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds
The in vitro activity of GR 20263, a new cephalosporin, was compared primarily with the activities of moxalactam (LY 127935… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)